If a patient has a mutation that disables thromboxane production in platelets, which consequence follows during vascular injury?

💡 Explanation

Thromboxane A2 (TXA2) is a key mediator for platelet aggregation because it promotes the activation of other platelets and increases their adherence to the injury site. Therefore, disabling its production impairs platelet aggregation, rather than accelerating other coagulation pathways.

• If a patient has undergone bariatric surgery reducing stomach size and altering digestive pathways, which consequence is most likely regarding drug absorption?
• What causes increased capillary filtration rate in inflamed tissue?
• If a sound engineer increases the compression ratio during audio mastering, which consequence follows for listener perception?
• Which failure mode becomes likely in asthma patients who overuse beta-agonist inhalers alongside environmental histamine exposure?
• Why does pulsatile GnRH secretion improve fertility outcomes compared to continuous GnRH administration during assisted reproductive technology?
• Why does blood pressure increase in atherosclerosis even if cardiac output remains constant?